Screener
Arcus Biosciences RCUS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
Based on trailing twelve months.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's EBITDA margin?
- Arcus Biosciences (RCUS) reported EBITDA margin of -406.8% in Q2 2026.
- How has Arcus Biosciences's EBITDA margin changed year-over-year?
- Arcus Biosciences's EBITDA margin decreased by 225.0% year-over-year, from -125.2% to -406.8%.
- What is the long-term trend for Arcus Biosciences's EBITDA margin?
- Over 5 years (2020 to 2025), Arcus Biosciences's EBITDA margin has grown at a -0.4% compound annual growth rate (CAGR), from -155.1% to -152.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Arcus Biosciences's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude